Inscription Capital LLC Purchases Shares of 1,978 Labcorp Holdings Inc. $LH

Inscription Capital LLC purchased a new stake in Labcorp Holdings Inc. (NYSE:LH) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,978 shares of the medical research company’s stock, valued at approximately $496,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Carmel Capital Partners LLC increased its holdings in Labcorp by 43.6% in the 4th quarter. Carmel Capital Partners LLC now owns 8,648 shares of the medical research company’s stock valued at $2,170,000 after buying an additional 2,627 shares during the period. UBS Group AG increased its holdings in Labcorp by 2.2% in the 4th quarter. UBS Group AG now owns 495,535 shares of the medical research company’s stock valued at $124,320,000 after buying an additional 10,706 shares during the period. Vanguard Group Inc. increased its holdings in Labcorp by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 9,850,631 shares of the medical research company’s stock valued at $2,471,326,000 after buying an additional 37,197 shares during the period. Resonant Capital Advisors LLC increased its holdings in Labcorp by 3.8% in the 4th quarter. Resonant Capital Advisors LLC now owns 3,773 shares of the medical research company’s stock valued at $947,000 after buying an additional 138 shares during the period. Finally, Concurrent Investment Advisors LLC increased its holdings in Labcorp by 20.1% in the 4th quarter. Concurrent Investment Advisors LLC now owns 3,296 shares of the medical research company’s stock valued at $827,000 after buying an additional 552 shares during the period. Institutional investors own 95.94% of the company’s stock.

Labcorp Stock Down 1.5%

Shares of NYSE LH opened at $259.58 on Wednesday. The firm’s 50-day simple moving average is $271.64 and its 200 day simple moving average is $267.63. The company has a market cap of $21.33 billion, a price-to-earnings ratio of 24.82, a price-to-earnings-growth ratio of 1.80 and a beta of 1.02. The company has a quick ratio of 1.23, a current ratio of 1.42 and a debt-to-equity ratio of 0.60. Labcorp Holdings Inc. has a 12-month low of $218.76 and a 12-month high of $293.72.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.12. The business had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, research analysts expect that Labcorp Holdings Inc. will post 17.67 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s dividend payout ratio is currently 27.53%.

Insider Transactions at Labcorp

In other Labcorp news, EVP Brian J. Caveney sold 1,500 shares of the stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total value of $429,465.00. Following the transaction, the executive vice president directly owned 30,107 shares in the company, valued at approximately $8,619,935.17. This trade represents a 4.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the stock in a transaction on Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the completion of the transaction, the executive vice president owned 2,579 shares in the company, valued at $734,782.89. The trade was a 17.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,113 shares of company stock valued at $4,547,450 over the last 90 days. 0.84% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Robert W. Baird boosted their target price on shares of Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Wall Street Zen downgraded shares of Labcorp from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Finally, Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $307.20.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.